文献速递复苏、休克与脓毒症心脑血管急症重症综合管理与镇静镇痛

院前大剂量糖皮质激素对院外心脏骤停复苏后患者炎症反应的影响:STEROHCA试验亚组研究

Inflammatory response after prehospital high-dose glucocorticoid to patients resuscitated from out-of-hospital cardiac arrest: A sub-study of the STEROHCA trial.
PubMed 文献 · Resuscitation · 2024-07-31
一句话结论院外心脏骤停复苏后单次院前注射甲泼尼龙250 mg可降低24小时促炎细胞因子水平,并升高入院时IL-10。

该研究为STEROHCA随机试验的预定义亚组分析,纳入137例院外心脏骤停患者,随机接受院前单次甲泼尼龙250 mg或安慰剂。于入院0、24、48、72小时检测血浆炎症标志物,采用混合模型分析对数转换数据。结果显示糖皮质激素组入院时抗炎细胞因子IL-10升高(比值2.74,95%CI 1.49-5.05,p=0.006),24小时促炎因子IL-6、IL-8、MCP-1、MIP-1b和TNF-α均显著降低。结论提示复苏后早期大剂量糖皮质激素可影响炎症反应,减少多种全身促炎细胞因子。

要点

  • 院外心脏骤停复苏后单次院前注射甲泼尼龙250 mg,24小时IL-6比值0.06(95%CI 0.03-0.10,p<0.001)。
  • 糖皮质激素组24小时IL-8比值0.53(95%CI 0.38-0.75,p<0.001),MCP-1比值0.02(95%CI 0.13-0.31,p<0.001)。
  • 糖皮质激素组24小时MIP-1b比值0.28(95%CI 0.18-0.45,p<0.001),TNF-α比值0.6(95%CI 0.4-0.8,p=0.01)。
  • 入院时糖皮质激素组抗炎细胞因子IL-10升高,比值2.74(95%CI 1.49-5.05,p=0.006)。
  • 180天生存率糖皮质激素组75%(51/68) vs 安慰剂组64%(44/69)。

适用人群与场景

  • 院外心脏骤停(OHCA)复苏后患者,纳入STEROHCA试验,共137例,中位年龄67岁(57至74)。
  • 院前场景接受单次注射干预。

处置流程与药物剂量

  • 院前单次注射甲泼尼龙250 mg(糖皮质激素组)或安慰剂(安慰剂组)。
  • 入院后0、24、48、72小时采集血浆样本检测炎症标志物。

研究设计与关键结果

  • 研究类型:随机对照试验STEROHCA的预定义亚组研究;样本量137例;人群为OHCA复苏后患者;干预为院前单次甲泼尼龙250 mg,对照为安慰剂。
  • 主要终点(炎症标志物动态):糖皮质激素组入院时IL-10比值2.74(95%CI 1.49-5.05,p=0.006);24小时IL-6比值0.06(95%CI 0.03-0.10,p<0.001),IL-8比值0.53(95%CI 0.38-0.75,p<0.001),MCP-1比值0.02(95%CI 0.13-0.31,p<0.001),MIP-1b比值0.28(95%CI 0.18-0.45,p<0.001),TNF-α比值0.6(95%CI 0.4-0.8,p=0.01)。
  • 180天生存率:糖皮质激素组75%(n=51/68),安慰剂组64%(n=44/69)。
  • 130例(95%)患者至少有一个血浆样本可用。

证据类型、等级与局限

  • 证据类型:随机对照试验(STEROHCA)的预定义亚组研究。
  • 局限:原文未报告局限性。

对床旁实践的改变

  • 作者认为,OHCA复苏后尽早给予大剂量糖皮质激素治疗可影响炎症反应,在24小时后降低多种全身促炎细胞因子。

指南或共识出处

  • STEROHCA试验,EudraCT编号2020-000855-11,2020年3月30日提交;ClinicalTrials.gov标识符NCT04624776。

提炼说明

  • 本条依据论文摘要整理;摘要未涉及「诊断标准与关键阈值」「红旗征与不能漏的情况」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开

BACKGROUND: The post-cardiac arrest syndrome (PCAS) after out-of-hospital cardiac arrest (OHCA) is characterized by a series of pathological events, including inflammation. In the randomized "STERoid for OHCA" (STEROHCA) trial, prehospital high-dose glucocorticoid decreased interleukin (IL) 6 and C-reactive protein levels following resuscitated OHCA. The aim of this predefined sub-study was to assess the inflammatory response the first three days of admission.

METHODS: The STEROHCA trial enrolled 137 OHCA patients randomized to either a single prehospital injection of methylprednisolone 250 mg or placebo. Inflammatory markers, including pro- and anti-inflammatory cytokines, were analyzed in plasma samples, from 0-, 24-, 48-, and 72 h post-admission. Mixed-model analyses were applied using log-transformed data to assess group differences.

RESULTS: The 137 patients included in this sub-study had a median age of 67 years (57 to 74), and the 180-day survival rates were 75% (n = 51/68) and 64% (n = 44/69) in the glucocorticoid and placebo group, respectively. A total of 130 (95%) patients had at least one plasma sample available. The anti-inflammatory cytokine IL-10 was increased at hospital admission in the glucocorticoid group (ratio 2.74 (1.49-5.05), p = 0.006), but the intervention showed the strongest effect after 24 h, decreasing pro-inflammatory levels of IL-6 (ratio 0.06 (0.03-0.10), p < 0.001), IL-8 (ratio 0.53 (0.38-0.75), p < 0.001), macrophage chemokine protein-1 (MCP-1, ratio 0.02 (0.13-0.31), p < 0.001), macrophage inflammatory protein-1-beta (MIP-1b, ratio 0.28 (0.18-0.45), p < 0.001), and tumor necrosis factor-α (TNF-α, ratio 0.6 (0.4-0.8), p = 0.01).

CONCLUSION: Administering high-dose glucocorticoid treatment promptly after resuscitation from OHCA influenced the inflammatory response with a reduction in several systemic proinflammatory cytokines after 24 h.

TRIAL REGISTRATION: EudraCT number: 2020-000855-11; submitted March 30, 2020. URL: https://www.

CLINICALTRIALS: gov; Unique Identifier: NCT04624776.

来源:Resuscitation,查看原文。版权归原作者所有。

参考来源

  1. Obling LER, Beske RP, Meyer MAS, et al. Inflammatory response after prehospital high-dose glucocorticoid to patients resuscitated from out-of-hospital cardiac arrest: A sub-study of the STEROHCA trial. Resuscitation. 2024. PMID: 39094677. doi:10.1016/j.resuscitation.2024.110340

供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。